Enliven Therapeutics (NASDAQ:ELVN) Raised to Hold at Zacks Research

Enliven Therapeutics (NASDAQ:ELVN) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Wednesday, Zacks reports.

A number of other research analysts also recently commented on the company. Morgan Stanley assumed coverage on Enliven Therapeutics in a report on Friday, October 2nd. They set an “overweight” rating and a $70.00 target price on the stock. Stifel Nicolaus boosted their price objective on Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Barclays initiated coverage on shares of Enliven Therapeutics in a research report on Tuesday, August 18th. They set an “overweight” rating and a $78.00 price target on the stock. Guggenheim reaffirmed a “buy” rating and set a $78.00 target price on shares of Enliven Therapeutics in a research note on Friday, November 6th. Finally, Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 7th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $75.44.

Enliven Therapeutics Trading Down 5.6%

ELVN opened at $48.31 on Wednesday. The company has a fifty day simple moving average of $46.65 and a 200 day simple moving average of $43.56. The firm has a market cap of $3.56 billion, a price-to-earnings ratio of -28.25 and a beta of 0.34. Enliven Therapeutics has a twelve month low of $14.78 and a twelve month high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.09. On average, analysts forecast that Enliven Therapeutics will post -1.70 earnings per share for the current fiscal year.

Insider Buying and Selling at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction that occurred on Monday, October 19th. The stock was sold at an average price of $38.48, for a total value of $231,572.64. Following the completion of the sale, the chief financial officer directly owned 38,000 shares in the company, valued at approximately $1,462,240. The trade was a 13.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director J. Scott Garland sold 13,000 shares of the company’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $46.67, for a total transaction of $606,710.00. Following the sale, the director directly owned 13,000 shares of the company’s stock, valued at approximately $606,710. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 31,054 shares of company stock worth $1,493,823. 3.00% of the stock is currently owned by company insiders.

Institutional Trading of Enliven Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ELVN. First Trust Advisors LP bought a new position in shares of Enliven Therapeutics during the 3rd quarter worth about $4,226,000. Voya Investment Management LLC grew its position in Enliven Therapeutics by 50.2% in the third quarter. Voya Investment Management LLC now owns 111,821 shares of the company’s stock valued at $5,126,000 after acquiring an additional 37,368 shares during the period. Russell Investments Group Ltd. increased its position in shares of Enliven Therapeutics by 3.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 95,440 shares of the company’s stock worth $4,375,000 after purchasing an additional 3,502 shares in the last quarter. Three Bridge Wealth Advisors LLC bought a new position in shares of Enliven Therapeutics in the third quarter valued at approximately $53,000. Finally, Pictet Asset Management Holding SA boosted its stake in Enliven Therapeutics by 14.1% in the third quarter. Pictet Asset Management Holding SA now owns 1,325,740 shares of the company’s stock worth $60,772,000 after purchasing an additional 163,956 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. Its research centers on precision oncology, with drug candidates designed to target specific proteins involved in tumor growth. The company’s pipeline has included ELVN-001, an investigational BCR-ABL1 inhibitor being studied for chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor developed for cancers driven by HER2. Enliven is based in Boulder, Colorado.